-
Ireland Reimburses Medical Marijuana-Based Drug For Chemotherapy-Induced Nausea And Vomiting
Monday, October 30, 2023 - 10:22am | 918Althea Group Holdings Limited (ASX: AGH), an Australian manufacturer of cannabis-based medicines and recreational cannabis products confirmed that Ireland’s Primary Care Reimbursement Service (‘PCRS’) has approved Althea THC20:CBD1 cannabis oil for...
-
Biogen Reveals $900M Settlement In Whistleblower's MS Drug Kickbacks Lawsuit Days Before Trial
Thursday, July 21, 2022 - 2:15am | 361Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlement agreement to resolve previously disclosed "qui tam" litigation related to its conduct before 2015. Qui tam is a type of whistleblower...
-
Montel Williams' Battle With Multiple Sclerosis And The Miracle Of Medical Marijuana
Friday, September 15, 2017 - 12:27pm | 945It was the year 2000. "The Montel Williams Show," one of the longest running talk shows in television history, was at its prime, making millions for CBS Corporation (NYSE: CBS). Montel was on a plane flying to Utah to record a guest part for "Touched by an Angel," when he felt...
-
Montel Williams Talks About His Cannabis Company And Its Emphasis On Patients
Tuesday, May 2, 2017 - 5:24pm | 1225TV personality Montel Williams was one of the keynote speakers at the Viridian Cannabis Investment Series, hosted by Viridian Capital Advisors at the John Jay School of Criminal Justice in New York City. Before his moving, personal speech on medical marijuana and the importance of patient care,...
-
Lingo Failure Leads Citi To Downgrade Biogen
Wednesday, June 8, 2016 - 10:03am | 261Biogen Inc (NASDAQ: BIIB) announced that anti-Lingo failed both the primary and the secondary endpoints in its Phase 2 RRMS trial. Citi’s Robyn Karnauskas downgraded the rating on the company from Buy to Neutral, while lowering the price target from $345 to $295. Lingo Failure “While...
-
4 Catalysts Coming For Roche Investors
Tuesday, October 13, 2015 - 2:25pm | 363After the release of positive data for Roche Holding Ltd. (ADR) (OTC: RHHBY)’s Ocrelizumab this weekend, Credit Suisse updated its model for the drug. The firm maintains an Outperform rating and $320.00 price target on the stock. Shares of Roche are up 1 percent on Tuesday trading. In a...
-
Mike Khouw Is Bullish On MS
Wednesday, June 16, 2010 - 6:47pm | 108Mike Khouw said on CNBC's Fast Money that he is looking at Morgan Stanley (NYSE: MS), and he is mildly bullish on this stock. Mike Khouw explained that he wants to sell the July 28 call for $0.25 and buy the July 26 call for $0.95. Additionally, he would sell the July 24 put for $0.60. This trade...